- ►diabetesjournals.org J Gerich, P Raskin, L Jean-Louis, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a randomized, multicenter,
double-masked, 2-year study of 428 drug-naïve patients with type 2 diabetes.
Patients received 120 mg ac nateglinide or 1.25 mg qd glyburide plus 500 mg ... Cited by 43 - Related articles - BL Direct - All 10 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
- Free from Publisher J Rosenstock, DR Hassman, RD Madder, SA … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Enrolled patients (n = 150) had received treatment
with diet and exercise in the previous 3 months with HbA 1c >7 and ≤12%.
Patients were randomized to receive monotherapy with repaglinide (n = 76) ... Cited by 60 - Related articles - BL Direct - All 6 versions
S Ristic, C Collober-Maugeais, E Pecher, F … - Diabetic Medicine, 2006 - pubmedcentral.nih.gov Re-use of this article is permitted in accordance with the Creative Commons
Deed, Attribution 2.5, which does not permit commercial exploitation. ... This
article has been cited by other articles in PMC. Cited by 8 - Related articles - BL Direct - All 7 versions
VA Fonseca, DE Kelley, W Cefalu, MA Baron, D … - Metabolism, 2004 - Elsevier Antidiabetic agents that augment insulin secretion can cause hypoglycemia. With
the current trend toward early and aggressive treatment of patients with type 2
diabetes, the hypoglycemic potential of insulinotropic agents is of ... Cited by 12 - Related articles - All 9 versions
FA Van de Laar, PL Lucassen, RP Akkermans, … - Cochrane database of systematic reviews (Online), 2005 - ncbi.nlm.nih.gov BACKGROUND: Alpha-glucosidase inhibitors such as acarbose or miglitol, have the
potential to improve glycemic control in type 2 diabetes mellitus. The true
value of these agents, especially in relation to diabetes related mortality ... Cited by 48 - Related articles - All 5 versions
CJ Bailey, A Bagdonas, J Rubes, SO McMorn, … - Clinical therapeutics, 2005 - Elsevier A total of 568 patients comprised the safety 1026 population (MET, 280; RSG/MET,
288) and 551 formed the intent-to-treat group (MET, 272; RSG/MET, 279). Baseline
characteristics of the safety population were comparable in the 2 groups; ... Cited by 46 - Related articles - All 4 versions
IW Campbell - International Journal of Clinical Practice, 2005 - medscape.com Therapy for type 2 diabetes mellitus should aim to control not only fasting, but
also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative,
restores postprandial early phase insulin secretion in a transient and ... Cited by 15 - Related articles - BL Direct - All 6 versions
M Marre, L Van Gaal, KH Usadel, M Ball, I … - Diabetes Obesity and Metabolism, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 45 - Related articles - BL Direct - All 4 versions
